Xiaoting Fei

Statistics

Publications

Citations

139

H-Index

Active since

2023

Affiliations

Hubei Polytechnic University(Current)

Lishui City People's Hospital

Wenzhou Medical University

Southern Medical University

Zunyi Medical University

Xiaoting Fei is an author at Hubei Polytechnic University specializing in oncology, cancer immunotherapy, and programmed cell death ligand 1 inhibition.

ORCID

Publications per year

2023–2024

Publications

HDAC-targeting epigenetic modulators for cancer immunotherapy

Binbin Cheng, Wei Pan, Yao Xiao et al. · European Journal of Medicinal Chemistry · 2024 · 92 citations · Full text

Medicine, Cancer Biology, Oncology +14

Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy

Shuanghu Wang, Zhihua Kong, Yaru Shi et al. · Journal of Medicinal Chemistry · 2024 · 18 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

Discovery of Novel <scp>d</scp>-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer Immunotherapy

Zongbao Ding, Shuanghu Wang, Yaru Shi et al. · Journal of Medicinal Chemistry · 2023 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17

Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024)

Binbin Cheng, Xian-Shi Ma, Yingxing Zhou et al. · European Journal of Medicinal Chemistry · 2024 · 13 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +11

1–4 of 4